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Abstract
Background: Atypical antipsychotics are increasingly used for treatment of mental illnesses like
schizophrenia and bipolar disorder, and considered to have fewer extrapyramidal effects than older
antipsychotics.
Methods: We examined efficacy in randomised trials of bipolar disorder where the presenting
episode was either depression, or manic/mixed, comparing atypical antipsychotic with placebo or
active comparator, examined withdrawals for any cause, or due to lack of efficacy or adverse
events, and combined all phases for adverse event analysis. Studies were found through systematic
search (PubMed, EMBASE, Cochrane Library), and data combined for analysis where there was
clinical homogeneity, with especial reference to trial duration.
Results: In five trials (2,206 patients) participants presented with a depressive episode, and in 25
trials (6,174 patients) the presenting episode was manic or mixed.
In 8-week studies presenting with depression, quetiapine and olanzapine produced significantly
better rates of response and symptomatic remission than placebo, with NNTs of 5–6, but more
adverse event withdrawals (NNH 12). With mania or mixed presentation atypical antipsychotics
produced significantly better rates of response and symptomatic remission than placebo, with
NNTs of about 5 up to six weeks, and 4 at 6–12 weeks, but more adverse event withdrawals (NNH
of about 22) in studies of 6–12 weeks. In comparisons with established treatments, atypical
antipsychotics had similar efficacy, but significantly fewer adverse event withdrawals (NNT to
prevent one withdrawal about 10). In maintenance trials atypical antipsychotics had significantly
fewer relapses to depression or mania than placebo or active comparator.
In placebo-controlled trials, atypical antipsychotics were associated with higher rates of weight gain
of ≥7% (mainly olanzapine trials), somnolence, and extrapyramidal symptoms. In active controlled
trials, atypical antipsychotics were associated with lower rates of extrapyramidal symptoms, but
higher rates of weight gain and somnolence.
Conclusion: Atypical antipsychotics are effective in treating both phases of bipolar disorder
compared with placebo, and as effective as established drug therapies. Atypical antipsychotics
produce fewer extrapyramidal symptoms, but weight gain is more common (with olanzapine).
There is insufficient data confidently to distinguish between different atypical antipsychotics.
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Background
Bipolar disorder is now recognised as a potentially treata-
ble psychiatric illness with substantial morbidity and
mortality and high social and economic impact [1]. There
is no cure, and every aspect of its definition, mechanisms
and treatment is subject to debate. Moreover, bipolar dis-
order is common, with an estimated lifetime prevalence
of 2%in a recent Canadian study [2], and of 3% for bipo-
lar I disorder in a US study [3].
Therapies must address the control of acute episodes
(manic, depressed or mixed), and maintenance of remis-
sion of symptoms. Drug treatments have included lith-
ium, anticonvulsants, and antipsychotics, but current
therapies have proven inadequate for many patients; only
half of bipolar patients achieve remission over two years,
and half of these relapse within the two years [4]. Issues in
drug treatment involve not only efficacy, but also tolera-
bility. Adverse events, including extrapyramidal symp-
toms and weight gain, can be significant and influence
adherence.
Newer (atypical) antipsychotics are generally considered
to have fewer extrapyramidal effects. They have proven
efficacy in treatment of acute mania and schizophrenia [5]
and have also been used in dementia [6]. Newer drugs are
often subjected to more, better, and more detailed inves-
tigation in randomised trials than older medicines.
Given the likely nature of randomised trials available, the
aim of this review was to:
1. Examine the efficacy in randomised trials of atypical
antipsychotics where the presenting episode is depression
or manic/mixed, comparing atypical antipsychotic with
placebo or active comparator.
2. Examine withdrawals for any cause, or due to lack of
efficacy or adverse events.
3. Combine all phases for adverse event analysis.
Potential sources of clinical heterogeneity in the studies
are types of patient, severity and duration of symptoms,
drug and dose used, the duration of therapy and/or study,
and the aim of therapy, whether for treatment of acute
symptoms or maintenance of remission. In addition there
may be differences in which outcomes were measured and
reported.
Methods
We searched PubMed, EMBASE and the Cochrane Library
up to December 2006 for randomised controlled trials
using atypical antipsychotic drugs to treat bipolar disor-
der. The search strategy used individual drug names,
"bipolar" and "random*", together with appropriate
indexing terms for bipolar disorder and randomised con-
trolled trial.
For inclusion trials had to be randomised and double
blind, and use an atypical antipsychotic drug alone or in
combination with a mood stabilising drug such as lith-
ium, valproate, divalproex, lamotrigine, or car-
bamazepine to treat adult patients with documented
bipolar disorder, with either a placebo or active compara-
tor. Trials had to have a minimum of 10 patients per treat-
ment arm, and a planned duration of at least three weeks.
The abstracts were read, and potentially useful reports
retrieved in full paper copy. Decisions on inclusion or
exclusion were made by consensus. No information was
taken from posters or abstracts, and studies were read
carefully to avoid including duplicate material. Studies
were scored for reporting quality using a common
method [7] utilising reporting of randomisation, blinding
and withdrawals. The maximum score possible was 5
points, and no study could be included with fewer than 2
points (one for randomisation and one for blinding).
Information extracted from the trials included details of
the patients (number, age, sex, nature of presenting epi-
sode), treatment regimens and concomitant medications.
We used the number of patients randomised and receiv-
ing at least a single dose of drug in order to have an inten-
tion to treat analysis; almost all outcomes were reported
in this way. Outcomes of efficacy, tolerability and harm,
and switching to the opposite state/pole were extracted,
using dichotomous data wherever possible. For efficacy
we particularly sought information on response and/or
remission, and for harm, information on weight gain,
extrapyramidal symptoms, and changes in prolactin, glu-
cose and lipid levels.
Guidelines for quality of reporting of meta-analyses were
followed where appropriate [8]. The prior intention was
to pool data where there was clinical and methodological
homogeneity, with similar patients, dose, duration, out-
comes, and comparators, but not where numbers of
events were small, and random chance could dominate
effects of treatment [9]. Homogeneity tests and funnel
plots, though commonly used in meta-analysis, were not
used here because they have been found to be unreliable
[10-12]. Instead clinical homogeneity was examined
graphically [13]. Relative benefit (or risk) and number-
needed-to-treat or harm (NNT or NNH) were calculated
with 95% confidence intervals. Relative benefit or risk was
calculated using a fixed effects model [14], with no statis-
tically significant difference between treatments assumed
when the 95% confidence intervals included unity. We
added 0.5 to treatment and comparator arms of trials in
which at least one arm had no events. Number-needed-to-BMC Psychiatry 2007, 7:40 http://www.biomedcentral.com/1471-244X/7/40
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treat (or harm) was calculated by the method of Cook and
Sackett [15] using the pooled number of observations
only when there was a statistically significant difference of
relative benefit or risk (where the confidence interval did
not include 1). Statistical significance of any difference
between numbers needed to treat for different drugs was
assumed if there was no overlap of the confidence inter-
vals, and additionally tested using the z statistic [16].
The following terms were used to describe adverse out-
comes in terms of harm or prevention of harm [17]:
• When significantly fewer adverse events occurred with
atypical antipsychotic than with control (placebo or
active) we used the term the number-needed-to-treat to
prevent one event (NNTp).
￿ When significantly more adverse events occurred with
atypical antipsychotic compared with control (placebo or
active) we used the term the number-needed-to-harm to
cause one event (NNH).
We chose only to pool data for analysis if there were at
least two trials and at least 250 patients [9]. We chose to
analyse according to comparator (placebo or active) and
trial duration, separating short-term trials of less than six
weeks, from those of six to 12 weeks. Longer duration tri-
als involved maintenance therapy following response to
treatment, and these were also analysed separately as trials
of longer than 12 weeks.
Results
We found five trials [18-22] in which the participants pre-
sented with a depressive episode, and 25 [23-49] (two
reported separately at two time points) in which the pre-
senting episode was manic or mixed. All had industry
sponsorship. Details of the included studies together with
outcome data extracted from the studies are provided for
presenting episode of depression [see Additional file 1]
and mania/mixed [see Additional file 2], as well as indi-
vidual adverse events [see Additional file 3], and a list of
excluded studies [see Additional file 4].
Reported outcomes were measured using some kind of
scale (depression or mania rating scales, weight, choles-
terol levels) [see Additional files 1 and 2], while other out-
comes, predominantly treatment emergent adverse
events, were elicited from patients as subjective evalua-
tions [see Additional file 3]. A few outcomes were
reported both using scale measurements and subjective
evaluations. Wherever the distinction was clear, both sets
of data are presented.
Efficacy
Presenting episode: depression
Five trials reported on 1,739 patients, 2206 of whom were
treated with an atypical antipsychotic. Mean ages in the
trials were 36 to 42 years, and just under half (44%) of
patients were men. Patients were diagnosed as Bipolar I
[18,21] or Bipolar I or II [19,20,22], and in one trial [20]
patients were excluded if they had failed to respond to at
least two classes of antidepressant in the current episode.
The trials were of mixed reporting quality, with one scor-
ing 5, and three 4, and one 3, out of a maximum 5 points.
Most patients (80%) were in three large placebo-control-
led trials [18,20,23] lasting eight weeks, one comparing
olanzapine monotherapy or olanzapine plus fluoxetine
with placebo, and the others comparing quetiapine mon-
otherapy, at different target dosages, with placebo. One,
small (30 patients), placebo-controlled trial lasting 12
weeks [19], examined a mood stabiliser together with ris-
peridone, paroxetine or a combination of the two. The
remaining patients were in an active controlled trial com-
paring olanzapine plus fluoxetine with lamotrigine [21].
All trials permitted limited use of benzodiazepines for the
first three to four weeks of treatment. The numbers of
patients treated with each drug are in Table 1, and dosage,
mean daily doses of trial drugs elsewhere [see Additional
file 1].
Response to treatment was generally defined as ≥50%
reduction in depression rating scale measurement, remis-
sion as ≤12 on MADRS or ≤7 on HAM-D, and emergence
of/switch to mania as YMRS ≥15 or 16. Results for the
three trials with placebo-only control groups [18,20,22]
are in Table 2 with analysis for individual monotherapy
using titrated doses of olanzapine [18] and quetiapine
monotherapy [20,22] against placebo combined and sep-
arately, but omitting olanzapine plus fluoxetine [18]
where there were fewer than 100 patients treated. For both
response and remission, all treatments were significantly
better than placebo, with a number-needed-to-treat
(NNT) of about 4–5 for quetiapine, and about 12 for
olanzapine alone; quetiapine was significantly better than
olanzapine. The combined NNT was about 6 for response
and 5 for remission. The rate of switch into a manic state
was low (2–6%), and not significantly different from pla-
cebo (4–7%) for either treatment.
All cause discontinuations were significantly less com-
mon for olanzapine than placebo. Discontinuations for
lack of efficacy were significantly less common in all active
treatment groups than placebo, with NNTps of about 7 to
11; the combined NNT to prevent one lack of efficacy dis-
continuation was 7 (95% confidence interval 5 to 9). Dis-
continuations for adverse events were significantly moreBMC Psychiatry 2007, 7:40 http://www.biomedcentral.com/1471-244X/7/40
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common for olanzapine alone and quetiapine than for
placebo (NNH 23 for olanzapine, 9 for quetiapine).
There were two trials with an active control. One [19] had
only ten patients in each treatment group, and the other
[21] demonstrated no large difference between lamotrig-
ine and olanzapine plus fluoxetine.
Presenting episode: mania or mixed
Twenty-five trials [23-49] reported on a total of 6,174
patients, 3,226 of whom were treated with an atypical
antipsychotic. Mean ages in trials were generally 35 to 43
years, and about half of patients were men (33 to 62% in
individual trials). Six trials specifically excluded patients
who had a history of intolerance to the experimental, or
similar, drugs [27,30,33,45,46,48] six excluded those with
a history of poor response [28,34,37,38,40,44], and six
excluded those with a history of either intolerance or poor
response [31,32,42,43,47,49]. In addition, five trials
excluded patients with rapid cycling [31,36,37,43,44].
Sixteen trials only reported outcomes at less than six
weeks (mostly three weeks). Six trials [39-44] reported at
six to 12 weeks (three reporting results also at three weeks
in the same report). Five trials [45-49] reported at times
longer than 12 weeks, (26 to 78 weeks); two of these trials
had previously reported three week results in separate
papers included in the 13 papers of less than six week
results. Papers were of good to high reporting quality,
with one scoring 2, 13 scoring 3, nine 4, and four 5, out of
a maximum 5 points. Points were lost due to inadequate
descriptions of randomisation/allocation or blinding
methods; all described withdrawals and dropouts.
Trials compared atypical antipsychotic as monotherapy or
in combination with a mood stabiliser, with placebo,
mood stabiliser monotherapy, or other active treatment
(divalproex or haloperidol). All trials permitted limited
use of benzodiazepines, usually with tapering dose over
the first two weeks, and all but four [30,32,44,49] permit-
ted use of anticholinergics for treatment of extrapyramidal
symptoms; prophylactic use was not permitted in any
trial. Details of dosage, mean daily doses of trial drugs,
and concomitant medication are in Additional file 2 [see
Additional file 2].
Table 1 shows the number of patients treated with each
drug, for periods of less than six weeks, 6–12 weeks, and
for longer than 12 weeks. The figures in Table 1 are larger
than the total number of patients because some trials
reported outcomes after more than one time. Because
some trials were only placebo-controlled, and others only
active-controlled, there were limits on the amount of
information available for analysis.
Response
Response to treatment was generally described as ≥50%
decrease in YMRS score (or equivalent) from baseline. For
placebo controlled trials lasting less than six weeks, there
was remarkable consistency for response between differ-
ent treatment regimens (Figure 1). Overall, for over 3,000
patients treated with either atypical antipsychotic or pla-
cebo, the relative risk was 1.6 (95%CI 1.5 to 1.8), with an
NNT of 5.1 (4.4 to 6.2). Results for individual drugs and
Table 1: Numbers of patients treated with different drugs in 
trials of atypical antipsychotics in bipolar disorder
Index 
episode and 
duration
Drug Number of 
Patients
Depression
8–12 weeks olanzapine 351
olanzapine/fluoxetine 287
quetiapine 661
risperidone + ms 10
risperidone/paroxetine + ms 10
paroxetine + ms 10
lamotrigine 205
placebo 685
Mania/Mixed
<6 weeks olanzapine 265
risperidone 449
risperidone + ms 127
quetiapine 209
quetiapine + ms 275
ziprasidone 270
aripiprazole 437
divalproex 126
haloperidol 428
haloperidol + ms 53
lithium 128
placebo 1126
placebo + ms 411
6–12 weeks olanzapine 291
olanzapine + ms 229
quetiapine 209
aripiprazole 174
divalproex 63
lithium 98
haloperidol 488
placebo 196
placebo + ms 115
>12 weeks olanzapine 567
olanzapine + ms 51
aripipazole 78
divalproex 126
lithium 214
placebo 219
placebo + ms 48
ms: mood stabiliser (lithium, valproate, divalproex, carbamazepine)BMC Psychiatry 2007, 7:40 http://www.biomedcentral.com/1471-244X/7/40
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combined therapy with a mood stabiliser had NNTs
between 4.3 and 6.1 (Table 3). In placebo controlled trials
lasting 6 to 12 weeks involving over 700 patients (Table
3), the relative risk was 1.6 (1.4 to 1.9) and the NNT 4.0
(3.1 to 5.6), again with very similar results in individual
trials (Figure 2).
For active controlled trials there were data for over 900
patients in trials lasting less than six weeks (Table 4), and
over 1,200 patients in trials lasting 6 to 12 weeks (Table
4), with no significant difference between treatments.
One study [44] individually showed aripipazole to be bet-
ter than haloperidol, but response rates in that trial were
low (Figure 3).
Only two trials reported on time to response. In one [27]
median response time was significantly shorter for olan-
zapine than divalproex, and in the other [39] it was
shorter for olanzapine plus mood stabiliser than for pla-
cebo plus mood stabiliser (18 vs 28 days).
Trials lasting longer than 12 weeks enrolled patients who
had already responded to treatment, and so response was
not an outcome measured or reported in these trials.
Remission
Remission was generally described as YMRS score of ≤12.
In placebo controlled trials lasting less than six weeks,
data for symptomatic remission were available for over
900 patients in four trials (Table 3), giving a relative risk
of 1.7 (1.4 to 2.0), and an NNT of 5.4 (4.0 to 8.1). At 6 to
12 weeks, in over 700 patients in three trials (Table 3), the
relative risk was 1.5 (1.3 to 1.7) and the NNT 4.0 (3.1 to
5.5). All atypical antipsychotics appeared to perform
equally well.
In active controlled trials there was no significant differ-
ence between treatments in trials shorter than six weeks
(Table 4). In trials lasting 6–12 weeks remission rates with
atypical antipsychotics (54%) were barely different than
those with active control (48%) (Table 4).
Three trials reported on median time to remission. It was
shorter for olanzapine than divalproex (14 vs 62 days;
[27,45]), shorter for olanzapine plus mood stabiliser than
placebo plus mood stabiliser (14 vs 22 days; [39]), but
similar for olanzapine and haloperidol (34 vs 29 days;
[41]).
Response rates with atypical antipsychotic and placebo in pla- cebo controlled trials lasting 6–12 weeks, where the present- ing episode was mania or mixed Figure 2
Response rates with atypical antipsychotic and placebo in pla-
cebo controlled trials lasting 6–12 weeks, where the present-
ing episode was mania or mixed. The inset scale relates the 
number of patients in the comparison.
0
20
40
60
80
100
0 2 04 06 08 0 1 0 0
Response (%) with atypical antipsychotic
Response (%) with placebo
0
250
500
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Table 2: Outcomes for placeo controlled trials in bipolar depression [18, 20, 22] – efficacy and discontinuations in trials lasting 8 weeks
Events/total patients Event rate (%)
Outcome Trials Treatment Placebo Treatment Placebo Relative Risk 
(95% CI)
NNT 
(95% CI)
Efficacy
Response
olanzapine 2–20 
mg/day
1 137/351 108/355 39 30 1.3 (1.04 to 1.6) 11.6 (6.4 to 62)
quetiapine 300–
600 mg/day
2 379/648 313/330 58 40 1.5 (1.3 to 1.7) 5.4 (4.2 to 7.7)
Combined 
atypical
3 516/999 240/685 52 35 1.4 (1.2 to 1.6) 6.0 (4.8 to 7.7)
Symptomatic 
remission
olanzapine 2–20 
mg/day
1 115/351 87/355 33 25 1.3 (1.06 to 1.7) 12.1 (6.7 to 62)
quetiapine 300–
600 mg/day
2 640/648 96/330 52 29 1.8 (1.5 to 2.2) 4.3 (3.5 to 5.9)
Combined 
atypical
3 455/999 183/685 46 27 1.6 (1.3 to 1.9) 5.3 (4.3 to 7.0)
Emergence of 
mania
olanzapine 2–20 
mg/day
1 19/345 23/345 6 7 0.8 (0.5 to 1.5) not calculated
quetiapine 300–
600 mg/day
2 23/697 18/347 5 3 0.6 (0.4 to 1.2) not calculated
Combined 
atypical
3 42/1042 41/692 4 6 0.7 (0.5 to 1.1) not calculated
Discontinuati
ons
All cause
olanzapine 2–20 
mg/day
1 191/351 232/355 54 65 0.8 (0.7 to 0.9) 9.1 (5.5 to 27)
quetiapine 300–
600 mg/day
2 292/702 132/349 38 42 1.1 (0.8 to 1.3) not calculated
Combined 
atypical
3 483/1053 364/704 46 52 0.9 (0.8 to 1.05) 17 (10 to 50)
Lack of 
efficacy
olanzapine 2–20 
mg/day
1 73/351 121/355 21 34 0.6 (0.5 to 0.8) 7.5 (5.1 to 15)
quetiapine 300–
600 mg/day
2 13/702 37/349 2 11 0.2 (0.1 to 0.3) 11 (7.7 to 20)
Combined 
atypical
3 86/1053 158/704 8 22 0.5 (0.4 to 0.6) 7.0 (5.6 to 10)
Adverse 
events
olanzapine 2–20 
mg/day
1 34/351 19/355 10 5 1.8 (1.1 to 3.1) 23 (12 to 220)
quetiapine 300–
600 mg/day
2 109/702 17/349 16 5 3.2 (2.0 to 5.2) 9.4 (6.7 to 14)
Combined 
atypical
3 143/1053 36/704 14 5 2.6 (1.8 to 3.7) 12 (10 to 14)
For discontinuations NNTp is shown in bold, indicating fewer events with treatment than placebo. More events with treatment than placebo, 
NNH, is in plain text. The trial with olanzapine included only the monotherapy treatment armBMC Psychiatry 2007, 7:40 http://www.biomedcentral.com/1471-244X/7/40
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Table 3: Outcomes for placebo controlled trials in bipolar mania (<6 weeks and 6–12 weeks)
Events/total patients Event rate (%)
Outcome Trials Treatment Placebo Treatment Placebo Relative Risk 
(95% CI)
NNT (95% CI)
Less than 6 weeks [24, 26, 28, 29, 
31-38, 42, 43]
Efficacy
Response
All mono- and adjunctive therapy 14 845/1634 473/1467 52 32 1.6 (1.5 to 1.8) 5.1 (4.4 to 6.2)
All monotherapy only 8 486/949 234/791 51 30 1.7 (1.5 to 2.0) 4.6 (3.8 to 5.8)
Olanzapine 2 69/125 41/129 55 32 1.8 (1.3 to 2.4) 4.3 (2.8 to 8.7)
Risperidone 4 276/502 157/478 55 33 1.7 (1.5 to 2.0) 4.5 (3.6 to 6.2)
Quetiapine 4 247/474 167/469 52 36 1.5 (1.3 to 1.7) 6.1 (4.4 to 9.8)
Aripiprazole 2 123/263 66/259 47 25 1.8 (1.4 to 2.3) 4.7 (3.4 to 7.6)
Symptomatic remission
All mono- and adjunctive therapy 4 210/448 128/453 47 28 1.7 (1.4 to 2.0) 5.4 (4.0 to 8.1)
All monotherapy only 2 83/182 44/179 46 25 1.9 (1.4 to 2.5) 4.8 (3.3 to 8.8)
Emergence of depression
Quetiapine, plus mood stabiliser 2 33/275 30/285 12 11 1.2 (0.7 to 1.8) not calculated
Discontinuations
All cause 13 513/1507 613/1350 34 45 0.7 (0.7 to 0.8) 8.8 (6.7 to 13)
Lack of efficacy 13 187/1507 306/1350 12 23 0.5 (0.5 to 0.6) 9.8 (7.7 to 13)
Adverse events 13 81/1507 66/1350 5.4 4.9 1.1 (0.8 to 1.5) not calculated
6 to 12 weeks [39, 42,43]
Efficacy
Response
All mono- and adjunctive therapy 3 268/428 116/309 63 38 1.6 (1.4 to 1.9) 4.0 (3.1 to 5.6)
Symptomatic remission
All mono- and adjunctive therapy 3 309/428 145/309 72 47 1.5 (1.3 to 1.7) 4.0 (3.1 to 5.5)
Emergence of depression
All mono- and adjunctive therapy 2 9/208 17/197 8.6 4.3 0.5 (0.2 to 1.1) not calculated
Discontinuations
All cause 3 151/438 154/313 34 49 0.8 (0.6 to 0.9) 6.8 (4.6 to 13)
Lack of efficacy 3 50/438 95/313 11 30 0.5 (0.3 to 0.6) 5.3 (4.0 to 7.7)
Adverse events 3 37/438 12/313 8.4 3.8 2.2 (1.1 to 4.4) 22 (13 to 80)
For discontinuations NNTp is shown in bold, indicating fewer events with treatment than placebo. More events with treatment than placebo, NNH, is 
in plain text
Trials lasting longer than 12 weeks enrolled patients who
had already responded to treatment with a lessening of
symptoms, and so remission was not an outcome meas-
ured or reported in these trials.
Emergence of depression
Emergence of depression was generally defined as MADRS
score of ≥18 with increase ≥4 from baseline on two con-
secutive occasions or at endpoint, or HAM-D score ≥15.
Few trials lasting up to 12 weeks reported on the emer-
gence of depression (Table 3). In placebo controlled trials
lasting up to 12 weeks, no trial individually reported a sig-
nificant difference, nor was there a difference when trials
were combined.
None of four active controlled trials lasting 6 to 12 weeks
that reported this outcome individually reported signifi-
cant difference between atypical antipsychotic and
haloperidol or lithium. However, when combined, these
trials with 1,000 patients reported significantly lower rates
of emergence of depression with atypical antipsychotic
(8%) than with active controls 13%) (Table 4), with a rel-BMC Psychiatry 2007, 7:40 http://www.biomedcentral.com/1471-244X/7/40
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ative risk of 0.6 (0.4 to 0.9), and a NNT to prevent one
emergent depression compared with active control of 21
(12 to 99). The active controls in this comparison were
haloperidol and lithium, and atypical antipsychotics
appeared to be particularly better than haloperidol (Fig-
ure 4). In the comparison with haloperidol alone in three
trials and 795 patients, the NNT to prevent one emergent
depression compared with haloperidol was 15 (9 to 48).
Relapse in maintenance trials
Trials lasting longer than 12 weeks were designed to inves-
tigate maintenance of remission, in terms of relapse into
Table 4: Outcomes for active controlled trials in bipolar mania (<6 weeks and 6–12 weeks)
Events/total patients Event rate (%)
Outcome Trials Treatment Active 
control
Treatment Active 
control
Relative Risk 
(95% CI)
NNT 
(95% CI)
Less than 6 
weeks [37, 42, 
43]
Efficacy
All mono- and 
adjunctive 
therapy
3 242/487 227/466 50 49 1.0 (0.9 to 1.2) not calculated
Symptomatic 
remission
All mono- and 
adjunctive 
therapy
3 137/333 126/322 41 39 1.1 (0.9 to 1.3) not calculated
Discontinuati
ons
All cause 4 75/346 90/338 22 27 0.8 (0.6 to 1.1) not calculated
Lack of efficacy 3 19/331 17/323 5.7 5.3 1.1 (0.6 to 2.1) not calculated
Adverse events 4 21/346 15/338 6.1 4.4 1.4 (0.7 to 2.6) not calculated
6 to 12 weeks 
[40-44]
Efficacy
All mono- and 
adjunctive 
therapy
4 394/616 353/585 64 60 1.1 (0.97 to 1.2) not calculated
Symptomatic 
remission
All mono- and 
adjunctive 
therapy
4 335/616 280/585 54 48 1.1 (1.01 to 1.3) 15 (8.2 to 110)
Emergence of 
depression
All mono- and 
adjunctive 
therapy
4 40/510 62/492 7.8 13 0.6 (0.4 to 0.9) 21 (12 to 99)
Discontinuati
ons
All cause 5 300/675 346/651 44 53 0.8 (0.8 to 0.9) 11 (7.1 to 30)
Lack of efficacy 5 119/675 94/651 18 14 1.2 (0.95 to 1.6) not calculated
Adverse events 5 68/675 132/651 10 20 0.5 (0.4 to 0.7) 9.8 (7.1 to 16)
For discontinuations NNTp is shown in bold, indicating fewer events with treatment than placebo. More events with treatment than placebo, 
NNH, is in plain text. Active comparators were haloperidol or lithiumBMC Psychiatry 2007, 7:40 http://www.biomedcentral.com/1471-244X/7/40
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an affective state. They were therefore were much longer
than 12 weeks; the range was 26 to 78 weeks.
In three placebo-controlled trials, with 589 patients
[46,48,49], 135/332 (41%) suffered any relapse (depres-
sive, manic or mixed) with atypical antipsychotic (olanza-
pine or aripiprazole), compared with 166/257 (65%)
with placebo. The relative risk of relapse was 0.6 (0.5 to
0.7), with an NNTp to prevent a relapse of 4.2 (3.1 to 6.2)
for olanzapine compared to placebo. Two active control-
led trials (487 patients) had slightly lower relapse rates
with olanzapine (32%) than lithium or divalproex (41%)
but the difference was barely significant with a relative risk
of 0.8 (0.6 to 0.98). Time to any relapse was longer for
olanzapine than placebo (174 vs 22 days; [46]) and for
olanzapine plus mood stabiliser than placebo plus mood
stabiliser (163 vs 42 days; [46]), but there was no signifi-
cant difference for olanzapine and lithium [47].
For relapse into a depressive state, there was bare signifi-
cant difference (upper limit of confidence interval 0.98;
Table 5) between atypical antipsychotic (25%), mostly
olanzapine, and placebo (31%) in three trials with 589
patients [46,48,49] (relative risk 0.8; 95% confidence
interval 0.6 to 0.98). For relapse into a manic state, there
was a significant difference between atypical antipsychotic
(12%), mostly olanzapine, and placebo (29%) in three
trials with 589 patients [46,48,49], with a relative risk 0.4
(0.3 to 0.6) and NNTp to prevent one manic relapse of 5.9
(4.2 to 9.5).
Discontinuations
All cause discontinuations were less frequent with atypical
antipsychotic than placebo in trials lasting less than six
weeks (Table 3), and 6–12 weeks (Table 3). Discontinua-
tions for lack of efficacy were also less common with atyp-
ical antipsychotic than placebo in trials lasting less than
six weeks and 6–12 weeks, with a similar NNTp as for all
cause discontinuations (Table 3). Discontinuations due to
adverse events were not significantly different from pla-
cebo in trials lasting less than six weeks, but more com-
mon in trials lasting 6–12 weeks (Table 3).
In active controlled trials discontinuations for any cause,
lack of efficacy or adverse events were not statistically dif-
ferent between treatments for trials lasting less than six
weeks, but in trials lasting 6–12 weeks, both all cause and
adverse event discontinuations were less common with
atypical antipsychotic than active control (Table 4).
In long-term maintenance trials olanzapine had more all
cause discontinuations than placebo, but fewer than
active comparators, though event rates differed considera-
bly (Table 5). Lack of efficacy and adverse event discontin-
uations did not differ significantly.
Adverse events
Some adverse events were measured using a scale with
predefined criteria; these include weight gain >7%,
extrapyramidal symptoms, and glucose and cholesterol
levels [see Additional files 1 and 2]. Other adverse events
were spontaneously reported by patients or elicited by
questions. Most trials reported events only if they
occurred in at least 10% of any treatment group, although
occasionally there was no lower limit or the limit was 5%,
or events were reported if there was a statistically signifi-
cant difference between groups [see Additional file 3].
Adverse events could be included in both categories. For
instance, weight gain may have been measured and gains
in excess of 7% reported as a pre-defined outcome, but
weight gain may also have been reported by patients as an
adverse event. Again, extrapyramidal symptoms may have
been prospectively assessed, but patients may also have
reported tremor or other symptoms.
Trials presenting with a manic, mixed or depressive epi-
sode were analysed together. Treatment emergent adverse
events were frequently described as mild or moderate, or
of limited duration, particularly somnolence or gastroin-
Response rates with atypical antipsychotic and comparator in  active controlled trials lasting 6–12 weeks, where the pre- senting episode was mania or mixed Figure 3
Response rates with atypical antipsychotic and comparator in 
active controlled trials lasting 6–12 weeks, where the pre-
senting episode was mania or mixed. The inset scale relates 
the number of patients in the comparison.
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testinal events. Few trials specifically reported the absence
of serious adverse events, or serious adverse events as a
separate category.
Measured adverse events
Weight gain >7% baseline
Predictably, short term trials lasting less than six weeks
found no significant difference between atypical antipsy-
Table 5: Outcomes in maintenance trials in bipolar mania – efficacy and discontinuations in trials lasting 26 weeks or longer [vs 
placebo 46. 48, 49 versus active 45, 47]
Events/total patients Event rate (%)
Outcome Trials Treatment Active 
control
Treatment Active 
control
Relative Risk 
(95% CI)
NNTp or 
NNH 
(95% CI)
Relapse
Any relapse
All versus 
placebo
3 135/332 166/257 41 65 0.6 (0.5 to 0.7) 4.2 (3.1 to 
6.2)
Olanzapine 
versus placebo
2 116/255 130/174 45 75 0.6 (0.5 to 0.7) 3.4 (2.6 to 
4.9)
Olanzapine 
versus active
2 79/250 96/237 32 41 0.8 (0.6 to 0.98) 11 (5.7 to 
250)
Depressive 
relapse
All versus 
placebo
3 84/332 79/257 25 31 0.8 (0.6 to 0.98) 18 (7.8 to 18)
Olanzapine 
versus placebo
2 75/255 68/174 29 39 0.7 (0.6 to 0.97) 10 (5.3 to 
200)
Manic relapse
All versus 
placebo
3 39/332 74/257 12 29 0.4 (0.3 to 0.6) 5.9 (4.2 to 
9.5)
Olanzapine 
versus placebo
2 33/255 55/174 13 32 0.4 (0.3 to 0.6) 5.4 (3.7 to 
9.4)
Discontinuati
on
All cause
All versus 
placebo
3 146/354 116/267 41 43 1.1 (0.9 to 1.3) not calculated
Olanzapine 
versus placebo
2 107/276 61/184 39 33 1.3 (1.04 to 1.7) 18 (6.9 to 30)
Olanzapine 
versus active
2 222/342 250/341 65 73 0.9 (0.8 to 0.98) 12 (6.5 to 67)
Lack of 
efficacy
All versus 
placebo
3 36/354 55/267 10 21 0.6 (0.5 to 0.9) 9.6 (6.2 to 22)
Olanzapine 
versus placebo
2 17/276 19/184 6 10 0.8 (0.4 to 1.4) not calculated
Olanzapine 
versus active
2 55/342 62/340 16 18 0.9 (0.6 to 1.2) not calculated
Adverse 
events
All versus 
placebo
3 27/354 9/267 8 4 2.4 (1.1 to 5.0) 24 (13 to 160)
Olanzapine 
versus placebo
2 22/276 8/184 8 5 2.0 (0.9 to 4.5) not calculated
Olanzapine 
versus active
2 72/342 80/340 21 24 0.9 (0.7 to 1.2) not calculated
For discontinuations NNTp is shown in bold, indicating fewer events with treatment than placebo. More events with treatment than placebo, 
NNH, is in plain text. Active comparators were haloperidol, lithium, or divalproexBMC Psychiatry 2007, 7:40 http://www.biomedcentral.com/1471-244X/7/40
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chotic (quetiapine, aripiprazole or ziprasidone) and pla-
cebo (Table 6). In trials lasting 6–12 weeks [20,43,45] and
over 12 weeks [46,48,49] significantly more patients
gained this amount of weight with quetiapine, olanzapine
and aripiprazole than with placebo.
In active controlled trials atypical antipsychotics olanzap-
ine (and olanzapine and fluoxetine) and quetiapine pro-
duced more weight gain than active comparators over 6–
12 weeks [21,43,45], as did olanzapine in trials lasting
more than 12 weeks [45,47] (Table 7).
Extrapyramidal symptoms
All trials assessed extrapyramidal symptoms using recog-
nised scales (SAS, BARS, AIMS). Few reported actual num-
bers of patients affected, but rather reported lack of
statistical difference [seeAdditional files 1 and 2]. Atypical
antipsychotics were reported to produce symptoms in sig-
nificantly fewer patients than haloperidol [37,41,43,44]
and lithium [42].
Prolactin, glucose, lipids
There were few statistically significant changes in labora-
tory values, and no pattern of change with any treatment.
Patient reported
Almost all trials did not report adverse events occurring
below a frequency of 10%, with some occasionally using
a lower threshold. In consequence, a number of adverse
events were reported sporadically (like constipation, or
nausea), making sensible analysis of them impossible.
Weight gain
In placebo-controlled trials of any duration above six
weeks, treatment emergent weight gain was reported to
occur at approximately the same rate as the rate of meas-
ured weight increase above 7% (Table 6) with both atypi-
cal antipsychotics (mainly olanzapine) and placebo. In
active controlled trials, weight gain was reported as an
adverse event less often than when it was measured as an
outcome of the trial, both for atypical antipsychotic
(mainly olanzapine) and active control (divalproex, lith-
ium, and lamotrigine) (Table 7).
Extrapyramidal symptoms
In placebo-controlled trials the frequency of akathisia was
higher than placebo in trials lasting less than six weeks,
but not those lasting 6–12 weeks (Table 6). Tremor was
more common in both. Where symptoms were reported
as extrapyramidal disorder, information was available
only for trials of less than six weeks, and in these short-
term trials the rate of reporting (20%) for atypical antip-
sychotics (risperidone and ziprasidone) was significantly
more common than with placebo (6%).
Compared with haloperidol and lithium, atypical antipsy-
chotics (olanzapine, quetiapine, and aripiprazole) pro-
duced significantly lower rates of akathisia in trials of 6–
12 weeks (Table 7). Tremor occurred at the same rate with
atypical antipsychotics (olanzapine and risperidone) as
with haloperidol and divalproex (Table 7) in trials of six
weeks or less, but significantly less frequently for olanza-
pine, quetiapine and aripiprazole (6%) than haloperidol
or lithium (21%) in trials lasting 6–12 weeks. In the single
trial using lamotrigine as active comparator, tremor was
reported at a higher rate with olanzapine plus fluoxetine
[21].
Somnolence
Somnolence occurred significantly more often with atypi-
cal antipsychotics than placebo in trials lasting less than
six weeks, or of 6–12 weeks (Table 6). In maintenance tri-
als lasting longer than 12 weeks somnolence was not sig-
nificantly different between atypical antipsychotic
(olanzapine) and placebo, but with only 32 events
reported in total, and at a much lower rate (6% with atyp-
ical) than in the shorter duration trials (26%–30%).
In active controlled trials somnolence was reported fre-
quently with atypical antipsychotic in trials of less than 6
Emergence of depression with atypical antipsychotic or  active comparator in placebo-controlled trials lasting 6–12  weeks, where the presenting episode was mania or mixed Figure 4
Emergence of depression with atypical antipsychotic or 
active comparator in placebo-controlled trials lasting 6–12 
weeks, where the presenting episode was mania or mixed. 
The dark symbol indicates lithium as the comparator, and the 
light symbols haloperidol. The inset scale relates the number 
of patients in the comparison.
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Table 6: Adverse events in placebo controlled trials
Events/total patients Event rate (%)
Event Trials Treatment Placebo Treatment Placebo Relative Risk 
(95% CI)
NNH/NNTp 
(95% CI)
Less than 6 weeks 
[24, 26, 28, 30-35 
37, 38]
Measured weight 
increase >7%
4 12/469 8/408 3 2 1.14 (0.5 to 2.8) not calculated
Treatment emergent 
weight gain
2 20/266 6/272 8 2 3.4 (1.4 to 8.4) 19 (11 to 59)
Treatment emergent 
akathisia
5 73/738 26/599 10 4 2.2 (1.4 to 3.5) 18 (12 to 35)
Treatment emergent 
extrapyramidal 
disorder
5 115/566 30/477 20 6 3.5 (2.4 to 5.1) 7.1 (5.6 to 10)
Treatment emergent 
tremor
5 46/618 16/529 7 3 2.5 (1.4 to 4.3) 23 (14 to 53)
Treatment emergent 
somnolence
11 340/1293 96/1244 26 8 3.5 (2.8 to 4.3) 5.4 (4.7 to 6.4)
Treatment emergent 
depression
2 10/145 10/144 7 7 1.0 (0.4 to 2.3) not calculated
6–12 weeks [20, 
22, 39, 41-43]
Measured weight 
increase >7%
4 136/1151 15/803 12 2 6.4 (3.9 to 11) 10 (8.3 to 13)
Treatment emergent 
weight gain
2 76/336 9/212 23 4 4.7 (2.5 to 9.1) 5.4 (4.2 to 7.6)
Treatment emergent 
akathisia
4 7/209 12/198 3 6 0.6 (0.2 to 1.4) not calculated
Treatment emergent 
extrapyramidal 
disorder
3 79/800 31/448 10 7 1.6 (1.04 to 2.4) 33 (16 to infinity)
Treatment emergent 
tremor
3 67/438 25/313 15 8 1.6 (1.1 to 2.5) 14 (8.5 to 36)
Treatment emergent 
somnolence
6 450/1487 109/1015 30 11 2.7 (2.2 to 3.3) 5.1 (4.4 to 6.1)
Treatment emergent 
depression
3 49/438 25/313 11 8 1.1 (0.7 to 1.7) not calculated
More than 12 
weeks [46, 48, 49]
Measured weight 
increase >7%
3 57/332 6/244 17 2 6.6 (3.0 to 15) 6.8 (5.2 to 9.9)
Treatment emergent 
weight gain
2 28/276 5/184 10 3 4.2 (1.6 to 11) 13 (9 to 32)
Treatment emergent 
somnolence
3 20/353 12/267 6 4 1.5 (0.7 to 3.0) not calculated
NNTp is shown in bold, indicating fewer events with treatment than placebo. More events with treatment than placebo, NNH, is in plain text
weeks (21%), 6–12 weeks (19%) and longer than 12
weeks (19%). It occurred more frequently than with active
controls (haloperidol, divalproex, lithium, or lamotrig-
ine) (Table 7).
Depression
Depression in mania trials did not occur more frequently
with atypical antipsychotic than with placebo in trials of
less than six weeks or of 6–12 weeks (Table 6). It was not
reported in longer duration comparisons with placebo. In
longer comparisons there was significantly more treat-
ment emergent depression with olanzapine than dival-
proex and lithium (Table 7).BMC Psychiatry 2007, 7:40 http://www.biomedcentral.com/1471-244X/7/40
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Discussion
An evidence-based approach to therapy requires certain
fundamentals in order to have confidence in a result, and
most confidence comes from systematic review and meta-
analysis of good quality randomised trials [50]. Trials
should be free from known sources of bias, as far as is
practically possible. This includes randomisation, blind-
ing, and using an intention to treat population, or at least
knowing about withdrawals and drop outs [51-53]. It also
includes having information on sufficient numbers of
patients [9].
This review extends that of Perlis et al, 2006 [54], which
included trials published to 2004, with 18 trials, 4,304
patients in the treatment of mania. This review also
includes depression, and included information from 27
trials published to end 2006 with 7,838 patients. In addi-
tion to pooling information from these trials on efficacy,
as did Perlis et al, we have also pooled information of
adverse events.
A number of other systematic reviews and meta-analyses
have addressed similar topics. Two Cochrane reviews
[55,56] report on olanzapine and risperidone in acute
mania. Other reviews have concentrated on particular
aspects – mania, for instance, [54,57,58], or bipolar
depression [59], or maintenance [60]. While generally
similar, they have tended to use different methods. For
instance, most concentrated on continuous outcomes, but
a problem with mean changes in rating scales is that they
can often be mean results of highly skewed distributions,
making the means meaningless [61]. This review concen-
trated on dichotomous outcomes reflecting clinically rele-
vant endpoints of efficacy and harm, and included four
atypical antipsychotics over the short, medium, and long
term, with trials included if they were published up to
Table 7: Adverse events in active controlled trials
Events/total patients Event rate (%)
Event Trials Treatment Active control Treatment Active 
control
Relative Risk
 (95% CI)
NNTp or NNH 
(95% CI)
Less than 6 weeks 
[27, 30, 37]
Treatment emergent 
tremor
3 24/331 26/323 7 8 0.9 (0.5 to 1.5) not calculated
Treatment emergent 
somnolence
3 69/331 47/323 21 15 1.5 (1.1 to 2.0) 16 (8.3 to 210)
6–12 weeks [21, 40, 
41, 42, 43]
Measured weight 
increase >7%
3 152/536 39/515 31 13 3.6 (2.6 to 5.0) 4.8 (4.0 to 6.1)
Treatment emergent 
weight gain
3 62/398 21/380 16 6 2.9 (1.8 to 4.6) 10 (7.0 to 17)
Treatment emergent 
akathisia
4 42/618 110/585 7 19 0.4 (0.3 to 0.5) 8.3 (6.4 to 12)
Treatment emergent 
extrapyramidal 
disorder
3 27/511 148/490 5 30 0.2 (0.1 to 0.3) 4.0 (3.4 to 4.9)
Treatment emergent 
tremor
4 39/618 122/585 6 21 0.3 (0.2 to 0.4) 6.9 (5.5 to 9.3)
Treatment emergent 
somnolence
5 133/705 72/684 19 11 1.8 (1.4 to 2.4) 12 (8.3 to 22)
More than 12 weeks 
[45, 47]
Measured weight 
increase >7%
2 93/340 43/337 27 13 2.2 (1.6 to 3.0) 6.9 (4.9 to 12)
Treatment emergent 
weight gain
2 45/342 25/340 13 7 1.8 (1.1 to 2.8) 17 (10 to 79)
Treatment emergent 
somnolence
2 64/342 31/340 19 9 2.1 (1.4 to 3.0) 10 (6.8 to 23)
Treatment emergent 
depression
2 88/342 63/340 26 19 1.4 (1.1 to 1.8) 14 (7.5 to 100)
NNTp is shown in bold, indicating fewer events with treatment than placebo. More events with treatment than placebo, NNH, is in plain text. 
Active comparators were haloperidol, lithium, or divalproexBMC Psychiatry 2007, 7:40 http://www.biomedcentral.com/1471-244X/7/40
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December 2006. Different approaches can be helpful in a
number of ways, perhaps principally in providing infor-
mation in ways that can be used by a wider audience.
There is an additional point of contention in systematic
reviews and meta-analysis that is relevant here, namely
how much it is acceptable to combine data from similar
but not identical interventions, participants, duration, or
outcome. We have chosen what we believe is a sensible
middle course. Efficacy data are shown by both combined
and by individual drugs (while recognising that numbers
for some outcomes for some drugs may be small). Adverse
events are not well reported, and we have chosen to com-
bine the data. Additional files have the results from indi-
vidual trials, so that others may perform analyses based
on their logic or preference.
Trial design and outcomes have also to be valid and use-
ful. This means, for instance, that in life-long illness we
have longer rather than shorter trials, or that trials study
appropriate patients without unrealistic exclusions or
inclusions. It also means that outcomes have to be clini-
cally relevant, and measured and reported in ways that are
useful. For instance, a mean change in a composite meas-
ure is less useful than knowing the number of patients
who have achieved an adequate level of response. Clinical
trials reported in journals are limited in the amount they
can report, and we know that using more detailed clinical
trial reports improves both data access and utility [62-64].
The trials included in this review were of good reporting
quality. All but one of the included trials scored 3 points
or more out of a maximum of 5, a level known to limit the
possibility of bias [52]. Points were lost due to inadequate
descriptions of randomisation/allocation or blinding
methods, and it was likely that allocation and blinding
was, in fact, better than reported.
Trials were disparate in terms of atypical antipsychotic
used, with olanzapine and quetiapine most commonly
used in depression and in mania studies of less than 12
weeks, and olanzapine and aripiprazole the only atypicals
tested in long-term maintenance studies. On the one
hand, dividing studies by type of presenting episode, by
duration, and by comparator, meant limiting the number
of patients in each group available for analysis. On the
other, combining these trials meant introducing a poten-
tially unacceptable level of clinical heterogeneity. We
chose to avoid this as much as possible by analysing by
presenting episode and duration, but combining different
atypical antipsychotics with a common comparator (pla-
cebo or active). There are potential problems with this
approach, exemplified by apparent differences in efficacy
between olanzapine and quetiapine in bipolar depression
(Table 2).
Reporting of outcomes in trials was limiting. Although the
number of patients experiencing response and remission
were reported, form many other efficacy outcomes like
depression and mania rating scores, or global impression,
were predominantly reported as mean changes only,
when it would be more useful to know how many patients
experienced clinically relevant outcomes. The clinical rel-
evance of some efficacy outcomes has also been chal-
lenged. For instance, re-analysis of an open-label
extension of a randomised trial suggested a better out-
come of sustained clinical recovery, where remission was
sustained for at least eight weeks, rather than just occur-
ring for any duration [65]. This outcome was not reported
in any trial included in the review, and if used would give
a much lower, but perhaps more realistic, impression of
efficacy.
Trials usually only reported adverse events occurring in at
least 10% of patients, so that for many events only spo-
radic information was available [see Additional file 3],
and no analysis of adverse events could be complete. In
addition, adverse event reporting could overlap. For
example extrapyramidal symptoms like tremor or aka-
thisia might be reported by patients alongside extrapy-
ramidal syndrome or symptoms measured using
recognised scales. Moreover, most trials permitted use of
medication to treat extrapyramidal symptoms when they
occurred, which could, of course, result in lower scores
than otherwise on symptom rating scales. Extrapyramidal
symptoms would still be recorded as spontaneous adverse
events. Because patients experiencing extrapyramidal
symptoms are more likely to withdraw or require dose
reduction, it is possible that use of anticholinergics may
have affected attrition rates, though related better to clin-
ical practice.
The evidence available allows a number of inferences.
Where the presenting episode was depression, both olan-
zapine and quetiapine appear to be efficacious over eight
weeks, with more responses and remissions than placebo,
and fewer lack of efficacy withdrawals. Adverse event
withdrawals were higher than with placebo. There is some
evidence that quetiapine at target doses of 300 or 600 mg
daily is more efficacious than olanzapine, but at the cost
of more adverse event discontinuations.
Where the presenting episode was mania, olanzapine, ris-
peridone, and quetiapine had similar event rates and
NNTs compared with placebo in trials shorter than six
weeks (Table 3). Combining all atypicals compared with
placebo, NNTs for response and remission were about 5.
In trials lasting 6–12 weeks, NNTs for response or remis-
sion were somewhat better, at about 4. This is generally in
accord with a previous meta-analysis [54], though that
review combined continuous data to come to the conclu-BMC Psychiatry 2007, 7:40 http://www.biomedcentral.com/1471-244X/7/40
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sion that atypical antipsychotics were superior to placebo.
Atypical antipsychotics produced fewer discontinuations
for any cause or lack of efficacy, but somewhat more
adverse event discontinuations in longer studies.
Limited comparison with active controls (lithium, val-
proate, haloperidol, lamotrigine) showed that there was
no major difference in efficacy or discontinuations, in
shorter duration trials. Perhaps notable, though, was a sig-
nificantly reduced rate of adverse event discontinuations
for atypicals than older active comparators in trials over
6–12 weeks.
Conclusion
In general, atypical antipsychotics are effective in treating
both phases of bipolar disorder compared with placebo,
and as effective as established drug therapies, though only
two (olanzapine and quetiapine) have been tested where
the presenting episode was depression. In general, atypi-
cal antipsychotics produce fewer extrapyramidal symp-
toms, but weight gain is more common with olanzapine
and quetiapine. There is insufficient data to confidently
distinguish between different atypical antipsychotics, pre-
dominantly due to the clinical heterogeneity engendered
by presentation, drug, dose, comparator, duration of trial,
and outcomes measured. Moreover, the weight of evi-
dence of efficacy in bipolar depression resides with olan-
zapine and quetiapine, and that on weight gain
overwhelmingly with olanzapine; extrapolation to other
drugs in the class may not be appropriate in these circum-
stances.
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